{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:08:51Z","timestamp":1787933331351,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-MPNs) are a group of malignant clonal disorders originating from bone marrow hematopoietic stem cells, and pulmonary hypertension (PH) is a serious progressive disease often coexisting with Ph-MPNs, with a prevalence ranging from 5 to 50%. The aim of this study was to analyze the prevalence, clinical characteristics, and associated risk factors of PH in 130 patients with Ph-MPNs, to investigate the impact of PH on patients\u2019 prognosis, and to provide a reference for the clinical identification of adverse prognostic factors and early prevention and treatment of PH. One hundred and thirty patients with Ph-MPNs treated at Beijing Anzhen Hospital from January 1, 2020 to December 31, 2024 were included in the study. PH risk was assessed by echocardiography (ECHO), and tricuspid regurgitation velocity (TRV)\u2009&gt;\u20092.8\u00a0m\/s was used as the criterion for high risk of PH. General information, hematological indices, biochemical indices, gene mutations and echocardiographic data of the patients were collected and statistically analyzed. The overall prevalence of PH among the 130 patients with Ph-MPNs was 15.4%. patients with PMF had the highest prevalence of PH (72.3%), which was significantly higher than that of patients with PV (9.9%) and ET (10.4%) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). patients in the PH high-risk group were older, had lower hemoglobin levels, and had a higher prevalence of splenomegaly and secondary myelofibrosis. the PH high-risk group Patients had a significantly higher mortality rate than the normal risk group (20% vs. 1.81%, <jats:italic>P<\/jats:italic>\u2009=\u20090.0004). Multifactorial Cox regression analysis showed that advanced age (HR\u2009=\u20091.029, <jats:italic>P<\/jats:italic>\u2009=\u20090.0332) and high risk of PH (HR\u2009=\u20091.034, <jats:italic>P<\/jats:italic>\u2009=\u20090.0432) were independent risk factors for patient survival.Logistic regression analysis showed that decreased hemoglobin (OR\u2009=\u20090.9657, <jats:italic>P<\/jats:italic>\u2009=\u20090.0062), splenomegaly (OR\u2009=\u20095.105, <jats:italic>P<\/jats:italic>\u2009=\u20090.0413) and secondary myelofibrosis (OR\u2009=\u20097.959, <jats:italic>P<\/jats:italic>\u2009=\u20090.0321) were independent risk factors for high risk of PH. This study revealed the prevalence of PH, risk factors, and their prognostic implications in patients with Ph-MPNs. It is suggested that regular monitoring of changes in relevant risk factors and vigilance and prevention of PH during the treatment of patients with Ph-MPNs are clinically important to improve the prognosis of patients.<\/jats:p>","DOI":"10.1007\/s00277-025-06334-w","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T04:57:46Z","timestamp":1745211466000},"page":"2279-2285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transformed to myelofibrosis is a risk factor for pulmonary hypertension in Philadelphia chromosome-negative myeloproliferative neoplasms"],"prefix":"10.1007","volume":"104","author":[{"given":"Dina","family":"Suolitiken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yini","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"7","key":"6334_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"issue":"1","key":"6334_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","volume":"10","author":"A Mocumbi","year":"2024","unstructured":"Mocumbi A et al (2024) Pulmonary hypertension. Nat Rev Dis Primers 10(1):1","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"6334_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s12185-020-02952-4","volume":"112","author":"Y Jindamai","year":"2020","unstructured":"Jindamai Y et al (2020) Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients. Int J Hematol 112(5):631\u2013639","journal-title":"Int J Hematol"},{"issue":"2","key":"6334_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5045\/br.2020.2020001","volume":"55","author":"M Lee","year":"2020","unstructured":"Lee M et al (2020) Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients. Blood Res 55(2):77\u201384","journal-title":"Blood Res"},{"issue":"12","key":"6334_CR5","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.echo.2019.07.010","volume":"32","author":"J Kim","year":"2019","unstructured":"Kim J et al (2019) Incremental utility of right ventricular dysfunction in patients with myeloproliferative Neoplasm\u2013Associated pulmonary hypertension. J Am Soc Echocardiogr 32(12):1574\u20131585","journal-title":"J Am Soc Echocardiogr"},{"issue":"38","key":"6334_CR6","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M et al (2022) 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43(38):3618\u20133731","journal-title":"Eur Heart J"},{"key":"6334_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejim.2019.08.004","volume":"68","author":"G Venton","year":"2019","unstructured":"Venton G et al (2019) Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. Eur J Intern Med 68:71\u201375","journal-title":"Eur J Intern Med"},{"issue":"3","key":"6334_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/ejh.13197","volume":"102","author":"M Brabrand","year":"2019","unstructured":"Brabrand M et al (2019) Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms. Eur J Haematol 102(3):227\u2013234","journal-title":"Eur J Haematol"},{"issue":"1","key":"6334_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00277-017-3165-9","volume":"97","author":"P Boddu","year":"2018","unstructured":"Boddu P et al (2018) Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97(1):109\u2013121","journal-title":"Ann Hematol"},{"key":"6334_CR10","doi-asserted-by":"crossref","unstructured":"Greenfield G, McMullin MF, Mills K (2021) Molecular pathogenesis of the myeloproliferative neoplasms. J Hematol Oncol, 14(1)","DOI":"10.1186\/s13045-021-01116-z"},{"issue":"1","key":"6334_CR11","first-page":"150","volume":"52","author":"E Sahin","year":"2022","unstructured":"Sahin E et al (2022) The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms. Turk J Med Sci 52(1):150\u2013165","journal-title":"Turk J Med Sci"},{"key":"6334_CR12","doi-asserted-by":"crossref","unstructured":"Kimishima Y et al (2021) Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. Nat Commun, 12(1)","DOI":"10.1038\/s41467-021-26435-0"},{"issue":"11","key":"6334_CR13","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/medicina57111181","volume":"57","author":"D Penna","year":"2021","unstructured":"Penna D (2021) New horizons in myeloproliferative neoplasms treatment: A review of current and future therapeutic options. Medicina 57(11):1181","journal-title":"Medicina"},{"issue":"5","key":"6334_CR14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1159\/000506596","volume":"29","author":"YT Yaylali","year":"2020","unstructured":"Yaylali YT et al (2020) Association of disease subtype and duration with echocardiographic evidence of pulmonary hypertension in myeloproliferative neoplasm. Med Principles Pract 29(5):486\u2013491","journal-title":"Med Principles Pract"},{"issue":"4","key":"6334_CR15","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3390\/ijms23042247","volume":"23","author":"PI Kuznetsova","year":"2022","unstructured":"Kuznetsova PI et al (2022) Red blood cell morphodynamics in patients with polycythemia Vera and stroke. Int J Mol Sci 23(4):2247","journal-title":"Int J Mol Sci"},{"issue":"137","key":"6334_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1183\/16000617.0041-2015","volume":"24","author":"Y Adir","year":"2015","unstructured":"Adir Y, Elia D, Harari S (2015) Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respiratory Rev 24(137):400\u2013410","journal-title":"Eur Respiratory Rev"},{"issue":"12","key":"6334_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4330\/wjc.v8.i12.703","volume":"8","author":"R Mathew","year":"2016","unstructured":"Mathew R et al (2016) Hematological disorders and pulmonary hypertension. World J Cardiol 8(12):703","journal-title":"World J Cardiol"},{"issue":"2","key":"6334_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/(SICI)1096-8652(199902)60:2<130::AID-AJH8>3.0.CO;2-Z","volume":"60","author":"G Garc\u00eda Manero","year":"1999","unstructured":"Garc\u00eda Manero G et al (1999) Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 60(2):130\u2013135","journal-title":"Am J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06334-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06334-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06334-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:13:58Z","timestamp":1746414838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06334-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6334"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06334-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Publishing consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}